Loading clinical trials...
Loading clinical trials...
Improved Hemodynamic Tolerance of Intermittent Hemodialysis Sessions in Intensive Care Unite (ICU) Using Citrate- vs Acetate-based Dialysate
During intermittent hemodialysis (IHD), the occurrence of intradialytic hemodynamic instability (IHI) is frequent in ICU and impacted morbidity and mortality. Bicarbonate dialysate buffer improves hemodynamic tolerance compared to acetate dialysate buffer. However, bicarbonate dialysate buffer still contains a lower concentration of acetate, which could contribute to hemodynamic instability. Recently, citrate-based dialysate in bicarbonate hemodialysis instead of acetate have been proposed. They have the appropriate authorizations for routine use. The aim of this study is to compare acetate- vs citrate-based dialysate in terms of hemodynamic tolerance and effectiveness.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Centre Hospitalier Béthune
Béthune, France
CHU
Caen, France
Centre Hospitalier Universitaire de Dijon
Dijon, France
CHRU Nancy
Nancy, France
Start Date
December 7, 2023
Primary Completion Date
July 1, 2027
Completion Date
July 1, 2027
Last Updated
January 6, 2026
48
ESTIMATED participants
ACETATE based dialysate
DEVICE
CITRATE based dialysate
DEVICE
Lead Sponsor
Centre Hospitalier de Bethune
Collaborators
NCT04163614
NCT07179705
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions